Biotech Matthew Herper STAT Plus: CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven
Biotech Jonathan Saltzman — Boston Globe STAT Plus: Takeda, already a giant in Mass. biopharma, plans a bigger footprint
Adam's Take Adam Feuerstein STAT Plus: A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology
